1. Introduction {#s0005}
===============

Novel-coronavirus (nCOVs) is spherical in shape, enveloped with single-stranded RNA, and considered as the largest viral RNA-genome (25--32 kb). Coronaviruses (CoVs) belongs to group of zoonotic viruses having enormous diversity of animal hosts i.e. birds & humans. The infection caused by CoV varies variably and greatly from asymptomatic-symptomatic to severe disease, depending on the species of virus and the host. This virus subdivided into four families: α, β, γ, δ-coronavirus. The γ, δ-CoVs are mainly infected birds, whereas α, and β-CoVs largely infected the mammals ([@b0535]).

Earlier, global spread of two β-coronavirus such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), origin from Foshan (China) in November 2002 ([@b0550]) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) occurred in Saudi Arabia in June 2012 ([@b0540]). At present, a novel coronavirus (SARS-CoV-2) reported first case in China (Wuhan) on December 2019, later on February 2020, World Health Organization ([@b0485]) given named as [@b0140] ([@b0245], [@b0490]). It has spread rapidly, affected many countries all over the world and declared by WHO, as COVID-19 emergency/outbreak, a pandemic ([@b0170]). SARS-CoV-2 is highly infectious and transmittable diseases, highly vulnerable to entire population worldwide via a directly contact with infected person through respiratory droplets ([@b0545]).

According to recent evidences, this epidemic also known as zoonotic disease, a disease transmitted from animals to humans. Several genealogical analyses documented that novel CoV considerably identical to the sequence of bat SARS-like coronavirus ([@b0045]). The replication and transcription phase of SARS-CoV-2 starts when virus (host) enters into the cell and interacting with spike proteins (S-protein) present at the surface of target receptor. Mainly two target receptors are present within the cell to which virus binds either with angiotensin converting enzyme-2 (ACE-2) receptor or with the serine protease TMPRSS2 ([@b0225]). However, exact mechanism is still unknown and need to investigate whether novel coronavirus employs ACE-2 and TMPRSS2 for the entry into the cytoplasm.

Novel-coronavirus infection is a community transmission disease, primarily affected person to person, via respiratory droplets ([@b0290]). Sometimes these droplets can land on objects and surfaces such as tables, doorknobs and handrail. In most of the cases, person can become infect by touching these objects and then touching their eyes, nose and mouth. The most common symptoms are fever, dry cough, tiredness, nasal congestion, sore throat and develop breathlessness. In severe cases patient symptoms can be characterized to organ failure i.e. kidney & respiratory. However, geriatrics population and person with preexisting medical condition (diabetes, hypertension, heart and lung problems) chances are higher for developing symptoms ([@b0370]). Apart from these symptoms this infection can be associated with lymphopenia, interstitial pneumonia and elevated levels of pro-inflammatory cytokines like as interleukins (ILs), interferons (IFNs), Granulocyte-colony stimulating factor (G-CSF), Tumor Necrosis Factor (TNF-α), etc. This condition sometimes also called "cytokine storm" can induce patient's death ([@b0210]). Currently, only symptomatic treatments are available to minimize the symptoms like self-isolation/quarantine, supplemental oxygen, mechanical ventilation, paracetamol for fever and antibiotics only for hospitalized patients for control bacterial co-infection. Till date, there are no vaccines or drug therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of this pandemic virus COVID-19 (β-coronavirus). Due to varying nature of this virus, development of novel pharmacological treatment takes several years. Many scientist or researchers work day and night and trying to focus on drug repurposing, which already are in use in some other conditions for competently control and spread of pandemic situation all over the world ([@b0275]).

From this review, our aim is to provide a basic overview about currently available drugs and drugs under clinical trial for COVID-19 patients. Based on many evidences from laboratory, animal and clinical studies, all are focusing on anti-viral, anti-inflammatory and immune-modulators drugs for the treatment of the novel-coronavirus. Here, we discussed all currently used treatment, under clinical development and outlook clinical trial for the treatment of COVID-19.

2. Drug therapy for COVID-19 {#s0010}
============================

Patients with COVID-19 characterized by abnormal in respiration rate (Hypoxia), hear rate, fever, irregular neutrophil counts (neutropenia), and higher level of plasma cytokines i.e. interleukins (IL-1, IL-6, etc.), and TNF-α. All these symptoms are the reason to promote disease severity. SARS-CoV-2 virus detected in both Types I and II pneumocytes present in the ciliated epithelial cells of nasal, bronchial and bronchiolar mucosae of respiratory system. Type I pnemocytes is responsible for gaseous exchange whereas Type II has main role in the production and secretion of surfactants. Destruction of both types of pnemocytesis, resulting in hypoxia and alveolar collapse. ACE-2 act as a target receptor for the treatment of COVID-19 infection, whereas TMPRSS2 protein, enhance the transmissibility of the virus. Increase in the production of leukocytes (neutrophil) leads to the formation of highly reactive oxygen species (ROS), and oxidative stress inside alveoli, resulting in the formation of mucus (cough) and alveolar damage. [Fig. 1](#f0005){ref-type="fig"} describes the potential targets with pathogenesis pathway for broad-spectrum antiviral agents, anti-inflammatory and immuno-modulatory agents in treatment of COVID-19.Fig. 1Schematic diagram of targets with pathogenesis pathway for broad-spectrum antiviral agents, anti-inflammatory and immuno-modulatory agents in treatment of COVID-19.

3. Antiviral agents {#s0015}
===================

Antiviral drugs are beneficial for several infectious diseases such as herpes, hepatitis, HIV, influenza and flu like symptoms ([@b0375]). Researchers and scientists are endeavoring to find drugs, which are effective in the treatment of COVID-19. Drug repurposing is widely acceptance at present, because of immediate impact of nCoVs outbreak into the society and public health emergency concern ([@b0340]). Many drugs that approved by USFDA for some other disease conditions are under preclinical and clinical development for the management of COVID-19. Here, we review and examine all the antiviral drug therapies and its relevance in the treatment of coronavirus as per available pharmacokinetic and pharmacodynamics data of clinical studies. Several studies has been documented that antiviral drugs delivered abruptly after beginning of symptoms and continue last up to 14 days (sputum peak around 5--6 days). These drugs minimizing the chances of infection to others by reducing release of virus from the host and replication into the respiratory secretions of infected person, and diminish risk of infection by prophylactic targeted treatment ([@b0330]).

Classification, mechanism of action, adverse effects and therapeutic uses of all antiviral agents (currently used and under clinical development) against COVID-19 are shown in [Table 1](#t0005){ref-type="table"} .Table 1Classification, mechanism of action, adverse effects and therapeutic uses of Antiviral agents against COVID-19.Name of Drug(s)ClassificationMechanism of actionAdverse effectsTherapeutic UsesSafety ConcernLopinavir/RitonavirHIV Protease inhibitorLopinavir inhibit key enzyme (Protease) of coronavirus life-cycle replication\
Ritonavir inhibits CYP3A4 enzymeDiarrhea, abdominal pain, nausea, dyslipidemiasHIV-1 &HIV-2 (anti-retroviral)Cautiously used in cardiac arrhythmias(QT-prolongation), hepatic diseaseRemdesivir (GS-5734)InvestigationalNucleoside analogueInhibit RNA dependent RNA polymerase (RdRp) enzymeNausea, vomiting,liver damageEbola, Marburg, SARS, MERS viral infectionsCaution for renal and hepatic impairment patientsRibavirinPurine nucleoside analogueInhibit GTP & viral RNA synthesisAnemia, bone marrow depression, hemolysis, GIT & CNS symptomsChronic hepatitis C, Influenza A & B, respiratory syncytial virus bronchiolitisContraindicated in pregnancy due to teratogenicityFavipiravir(T-705)/UmifenovirInvestigational RNA-Dependent RNA Polymerase InhibitorInhibits viral RNA-synthesisGIT and CNS symptoms, abnormal liver enzyme, elevations in serum uric acidInfluenza arenavirus, bunyavirus filovirus, Ebola &Lassa virusContraindicated in pregnancy due to teratogenicityDarunavir/cobicistatProtease inhibitorInhibit key enzyme of coronavirus life-cycle replication Protease (M^pro^)/inhibition of human CYP3A4 proteinNausea, diarrhea, vomiting, muscle ache headache, joint pain,HIV/AIDS (used in HIV-1 type virus)Cautiously used in liver (hepatitis B & C), kidney, hemophilia, diabetes and heart patientsCamostatmesilate/nafamostatSerine protease inhibitorInhibits enzyme activity TMPRSS2 receptorOedema, urticaria, GIT-intolerance, abnormal liver enzymeAcute Pancreatitis, postoperative reflux esophagitisHepatic diseasesIvermectinAntiparasiticInhibits RNA viral synthesispruritus, giddiness, nausea, abdominal pain, constipation and lethargyAnthelmintic, Onchocerciasis, strongyloidiasis, scabies, pediculosisPregnant women and young children

3.1. Lopinavir/Ritonavir {#s0020}
------------------------

Lopinavir (LPV) and ritonavir (RTV) are effective agents that inhibit the protease activity of coronavirus. LPV and RTV act as an antiretroviral used for the treatment of AIDS/HIV virus (HIV-1& HIV-2). RTV enhances the plasma concentration of LPV through inhibition of cytochrome P450 (CYP3A)-mediated metabolism of LPV ([@b0425]). Previous studies reported that LPV blocks virus replication in the later stages steps of MERS-CoV cycle ([@b0150]) and abate the activity of SARS-CoV by inhibition of proteinase activity ([@b0255]). In a randomized, controlled and open-label trial involving 199 adults SARS-CoV2 positive patients, patients were divided into two groups (LPV-RTV treated & standard-care group). There is no remarkable changes were observed in both the groups in terms of improvement and mortality. Moreover, adverse effects were less common in LPV-RTV, as compared to standard-care group ([@b0085], [@b0090]). Another study reported that, patients were assigned randomly in phase 2-trial and administered 14 days combination of LPV (400 mg), RTV (100 mg) and ribavirin (400 mg) in every 12 h with IFN beta-1b to improve the antiviral response. This combination seems to be better, superior and provides best output to LPV-RTV alone and also diminished the virus desquamation, reduces symptoms of patients, and often promoting discharge of patients in the mild-moderate COVID-19 ([@b0250]). Another *in vitro* study reported that Ribavirin, analogue of guanosine nucleotide having wide spectrum of antiviral activity, used along with LPV/RTV to treat SARS-COV-2 viral infection in china (ChiCTR2000029387) ([@b0305]). Earlier this combination was well-established for the treatment of SARS-CoV infection along with minimal risk of acute respiratory distress syndrome (ARDS) and mortality rate ([@b0115]). Moreover, future clinical studies are needed to check this combination with other antiviral-combination against SARS-CoV-2.

3.2. Remdesivir (RDV, GS-5734) {#s0025}
------------------------------

The drug was developed in 2017, for the treatment of Ebola and Marburg virus infections. RDV is a prodrug of nucleotide (adenosine) analogue and having a broad-spectrum antiviral activity. In body, it is metabolized into active metabolite GS-441524. The antiviral mechanism of RDV is to inhibit RNA-dependent RNA polymerase (RdRp) enzyme, necessary for virus replication ([@b0010]). Earlier *invitro* studies reported that RDV inhibits single stranded RNA virus replication such as SARS-CoV and MERS-CoV ([@b0005]).Another mouse model study reported that combination of RDV and IFN-beta is better than LPV& RTV for the treatment of MERS-CoV ([@b0415]). Currently preclinical study reported that association of RDV & chloroquine is greatly efficient for preventing SARS-Cov-2 infection ([@b0480]). In addition, phase 3 clinical trials conducted in 237 participants to check efficacy and safety of the RDV (loading dose, 200 mg on day 1 only followed by 100 mg maintenance dose, OD for 9 days) in COVID-19 patients ([@b0080]). RDV shows promising output in some of the US patients with COVID-19 ([@b0230]). Furthermore, [@b0040] reported remdesivir shows possible efficacy better as compared to placebo group in hospitalized patients for the treatment of SARS-CoV-2 virus. A randomized, double-blind and placebo-controlled clinical trial has been conducted and the patients received remdesivir i.v. {day1 loading dose (200 mg) + daily maintenance dose (100 mg) up to 9 additional days}. Patients are assigned randomly and total of, 1063 infected patients are enrolled and divided into two groups, remdesivir group: 541 patients and placebo group: 522 patients. The overall time to recovery rate is better in remdesivir and also lowers infection in respiratory system as compared to placebo. In addition, various evidences suggested serious adverse event i.e acute respiratory failure and sudden death in few patients and strict monitoring is required to manage dose at the time of treatment. From this report, we can conclude antiviral treatment always need supportive care or supplemental oxygen to prevent other negative outcomes. Recently, [@b0120] pharma company launched COVIFOR vials, brand name of remdesivir, a game-changer drug for treatment of COVID-19. This drug is restricted used in patients who already have kidney problems, pregnant and lactating women (<https://www.pharmaceutical-technology.com/news/cipla-hetero-remdesivir-covid-19/>). Hence, further research is requisite to evaluate its pharmacological and pharmacodynamics characteristics against SARS-CoV-2 virus.

3.3. Favipiravir (FPV) & Umifenovir {#s0030}
-----------------------------------

Favipiravir (Avigan) is an antiviral drug, firstly developed by Japan in the year 2014, for treatment of influenza virus infections ([@b0195]). It is a nucleotide (guanine) analogue, & converted into active metabolite by phosphorylation, then inhibits the synthesis of RNA (RdRp) and virus mutagenicity ([@b0475]). It has been documented by *invitro* study that FPV inhibits SARS-CoV-2 in Vero E6 cell (EC~50~ = 61.88 μM) ([@b0175]). An open & controlled study designed to determine the efficacy of FPV (1600 mg BD, on day 1 followed by 600 mg BD on 2--14 days) Vs LPV/RTV (400 mg/100 mg BD) along with IFN-α1b, BD) for the treatment of COVID-19. Preliminary results showed that there is significant difference between viral clearance & chest improvement rate ([@b0065]). In India, Glenmark is the first company to initiates the Phase 3 trials on FPV by enrolled 150 participants, duration of treatment maximum of 14 days and total study duration of an individual maximum upto 28 days, with mild to moderate COVID-19 under restricted emergency used. Recently, on June 22, 2020 glenmark permitted FPV, under brand name of Fabiflu tablets (1800 mg BD on first day followed by 800 mg BD from day 2 to day 14) into the market for treatment of mild to moderate cases of COVID-19 patients ([@b0030]).

Umifenovir (Arbidol) is a dual-acting direct antiviral/host-targeting agent used as a prophylaxis in the influenza and respiratory infections. A cohort study enrolled 102 adult patients characterized by lymphopenia showed no significant difference in the results obtained between the survival and non-survival groups by receiving treatment with antiviral, antibiotic and glucocorticoid therapy. However, there is a significant data and less mortality rate for those patients who receive arbidol ([@b0085], [@b0090]).

3.4. Darunavir/cobicistat {#s0035}
-------------------------

This combination of drug used as an antiretroviral in the treatment of HIV/AIDS. Darunavir is a HIV protease inhibitor and cobicistat enhances the plasma concentrations of darunavir by blocking its metabolism by CYP 450 enzyme ([@b0155]). Preclinical studies documented that this combination showed beneficial effects in the SARS-CoV-2 virus infections ([@b0295], [@b0350]). The effectiveness and safety concern of darunavir/cobicistat combination is being evaluated under development of clinical trials phase 3 by enrolling 30 COVID-19 patients and estimated completion of study on December 31, 2020. Lastly, the primary outcomes measures shows the clearance rate of virological salivation, less throat infections and decreases respiratory secretion at day 7 (Time frame: 7 day after first randomization) ([@b0310]).

3.5. Camostatmesilate/nafamostat {#s0040}
--------------------------------

Initially, Camostatmesilate and Nafamostatare used in postoperative reflux esophagitis and in chronic pancreatitis ([@b0460]). Camostatmesilate and Nafamostat, both drugs act on attractive target TMPRSS2, a serine protease inhibitor and block the entry of the virus into the lung alveolar cells ([@b0225]). Recently, Camostat mesilate enters into the phase 2 trials by taking 114 participants (administered dose approx. 200 mg for 7 days, TID). The outcomes obtained like changes in COVID-19 symptoms (frequency and severity), body temperature and changes entry in SARS-CoV-2 viral load.

3.6. Ivermectin {#s0045}
---------------

Ivermectin is a FDA approved drug, used as an anti-parasitic and in the treatment of many types of virus infections such as HIV, dengue, influenza and Zika ([@b0070]). Recent study showed that Ivermectin, inhibits the growing of virus in cell culture approximately for 48 hrs. Till date, test is only carried out *in-vitro*, for confirmation, strong clinical trials are needed to evaluate its safety and efficacy in the treatment of COVID-19 patients ([@b0400]).Clinical studies of Ivermectin in COVID-19 patients are underway by enrolling 50 confirmed cases of COVID-19, as per hospital protocol. This study is in progress and might be getting its primary outcomes about its safety and clinical efficacy by theend of July 2020 ([@b0060]).

4. Anti-inflammatory and immunomodulatory agents {#s0050}
================================================

Earlier data about coronavirus (SARS & MERS) showed, cell infiltration and cytokine storm (CS) leads to acute cell lung injury, ADRS and death of many patients ([@b0100], [@b0110]). Recently, COVID-19 infection, which is due to SARS-CoV-2 virus, accompanied by rapid replication of virus and a massive release of cytokine profile as same in other two reported coronavirus SARS and MERS ([@b0445]). Currently, study documented that cytokines like interleukins (IL-1B, IL-6, IL-7, IL-9 & IL-10); G-CSF; IFNs; interferon-γ-inducible protein (IP10); monocyte chemoattractant protein (MCP1), tumor necrosis factor (TNFα), vascular endothelial growth factor (VEGF), platelet derived growth factors (PDGF) and other pro-inflammatory mediators are increase in COVID-19 patients([@b0240]). Another studies reported extensively elevation in the level of IL-6 in critically severe poorly in COVID-19 infected patients ([@b0385], [@b0555]). Classification, mechanism of action, adverse effects and therapeutic uses of all anti-inflammatory and immunomodulatory drugs (currently used and under clinical development) against COVID-19 are listed in [Table 2](#t0010){ref-type="table"} **.** Table 2Classification, Mechanism of action, adverse effects and therapeutic uses of Anti-inflammatory &Immunomodulatory agents against COVID-19.Name of Drug(s)ClassificationMechanism of actionAdverse effectsTherapeutic UsesSafety ConcernChloroquine/Hydroxy-chloroquine (HCQ)4-aminoquinolonesInhibit viral DNA & RNA polymerase enzyme, viral protein glycosylation, ACE2 receptor, also inhibit cytokine release immune-modulationCardiovascular symptoms (prolongation of QT interval)Antimalarial, Immuno-modulatorCautiously used in liver & heart damage, GIT, retinal, neurological & hematological diseasesAnakinraBiological agentsRecombinant human IL-1 receptor antagonistFever, chills, sweating, cough, sore throat, nausea, vomiting, diarrhea, stomach painRefractory rheumatoid arthritisCaution in patients with thrombocytopenia & neutropenia, infusion related reactionsCanakinumab (ACZ885)Human monoclonal antibodyIL-1β receptor antagonistCNS (headache, vertigo), GI symptoms, musculoskeletal pain, rhinitis, bronchitisPeriodic fever syndromes, Sudden Juvenile Idiopathic Arthritis (SJIA)Caution in patients with thrombocytopenia & neutropeniaTocilizumab/ItolizumabHumanized monoclonal antibodyIL-6 receptor antagonistAllergic reactions, headache, hypertension, mouth ulcers, increase in hepatic enzymesAutoimmune disorder/immunosuppressive effects (rheumatoid arthritis, giant cell arteritis)Contraindicated in hepatic diseases, GIT perforation patients, infusion related reactionsAviptadilVasoactive intestinal polypeptide (VIP) analogueInhibits production ofIL-6 and TNF-αAlterations in blood pressure, Heart rateErectile dysfunction, sarcoidosis, acute lung damageCautiously used in cardiovascular patientsEculizumabProtein Based Therapies\
Monoclonal antibody (mAb)Inhibitor of the terminal portion of complement cascadeAllergic reactions, anemia, GIT & flu like symptoms, headache & leukopeniaAtypical hemolytic uremic syndrome, generalized myasthenia gravisContraindicated in patients with unresolved serious Neisseria meningitides infectionBaricitinibTyrosine protein kinase familyJanus-kinase (JAK1 & JAK 2) inhibitorsAllergic reactions, increased LDL cholesterol, nausea, trouble in breathingAutoimmune disease (rheumatoid arthritis)Contraindicated in kidney and liver diseases (hepatic B&C), bone-marrow depression and cancer

4.1. Chloroquine/Hydroxychloroquine (HCQs) {#s0055}
------------------------------------------

It is an anti-malarial and over the counter (OTC) drug, activity similar to chloroquine. Recently, it was reported that HCQs shortened the time to clinical recovery on the SARS-CoV-2 patients. Due to its interferon blocking property, it has diminished the immune response to a viral infection. This immunomodulatory property makes its useful in autoimmune disorder such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The safety profile of HCQ is superior as compared to chloroquine during long term used in COVID-19 patients and little concern about drug-drug interactions ([@b0530]). Several *in vitro* studies reported CQs/HCQs are used as an effective treatment in SARS-CoV-2 virus. As they are weak bases and enhance pH of endosomal in host cell organelles, inhibit fusion of autophagosome-lysosome and inactivates enzyme require for replication of virus. They also have a potential to deactivate ACE-2 glycosylation, for which coronavirus may enters into the cell ([@b0185]). Currently studies showed that HCQ administered for 3--6 days, effective in clearing viral nasopharyngeal carriage of SARS-CoV-2 in most of the COVID-19 patients and strengthen its effects along with azithromycin ([@b0200]). Azithromycin, a macrolide antibacterial drug was shown to be successful in the treatment of zika and ebola viruses by *in-vitro* studies ([@b0315], [@b0055]). Previous studies reported that combination of HCQ and azithromycin showed synergistic effect and prevent respiratory tract infections when administered by viral infection patients ([@b0025]).

Recently, World Health Organisation (WHO) updated information on 17 June 2020, about safety and efficacy of chloroquine (CQs)/Hydroxychloroquine (HCQs) and compared it with standard care treatment for COVID-19 patients. The overall outcomes showed that there is no significant difference in case of mortality when compared with standard care treatment. In addition, some reports evaluated HCQs cause's serious adverse effects like prolongation of QT interval, ventricular fibrillation, arrhythmia and sometimes leads to abrupt death. The safety and efficacy assurance for CQs/HCQs, there is necessitate that other clinical studies are needed to be performed and exemplify with safety concern ([@b0125]). Further, US FDA summarized details on July 1 with safety concern, and permitted used of CQs/HCQs is now accessible to take care of patients with COVID-19 but some strict monitoring are required while treatment as it shows various heart related problems, blood and lymph disorders, renal injury and hepatic failure ([@b0465]).

4.2. Interferon (IFNs) β-1b {#s0060}
---------------------------

Interferons are types of cytokines effective in the management of infections & infectious diseases ([@b0015]). It is a broad-spectrum antiviral, antiproliferative & immunomodulatory drug interacting with the toll-like receptors and inhibits viral replication and protein synthesis ([@b0455]). There are three types of IFN (α, β, and γ). IFN-β shows high potent specificity as compared to IFN-α in reducing the replication of MERS-CoV ([@b0215], [@b0410]). Recently, *ex-vivo* studies demonstrated SARS-CoV-2 triggers lower type 1 interferon than SARS-CoV in human lung tissue ([@b0410]). Further, several future studies are being conducted to determine its efficacy & safety along with other antiviral drug in treatment of COVID-19.

4.3. Interleukin antagonist {#s0065}
---------------------------

Interleukin plays a major role in the pathogenesis of all three coronavirus SARS-CoV-1, MERS & SARS-CoV-2 infections ([@b0285]). Recent study reported several pro-inflammatory mediators plays a major role in the lung damage such as interleukins (IL-2, IL-6 etc) and inflammatory markers (D-dimer, ferritin, and C-reactive protein) ([@b0130], [@b0280]). Several ILs antagonist drugs are under ongoing trials to check its safety and efficacy against SARS-CoV-2 viral infections.

### 4.3.1. Anakinra (IL-1 Antagonist) {#s0070}

Anakinra is a recombinant IL-1 receptor antagonist and may be helpful in COVID-19 patients. It prevents the binding of IL-1α and IL-1β to interleukin-1 receptors, which is used in the treatment of autoimmune disorders ([@b0095]). Recently, retrospective cohort study showed high dose of anakinra (5 mg/kg, BD,iv) produces beneficial and efficacious effects in 72% Covid-19 infected patients associated with ARDS ([@b0095]). In addition, anakinra alleviated hyper-inflammation and respiratory distress in SARS-CoV-2 infected patients ([@b0450]). Another studies reported anakinra (100 mg repeated after 6 h, sc for 7 days) administered along with remdesivir (200 mg LD, followed by 100 mg after 4 h, iv for 7 days) used in the treatment of respiratory dysfunction in COVID-19 patients ([@b0190]). However, several clinical trials in large population are required for confirmation of its efficacy.

### 4.3.2. Canakinumab (IL-1β Antagonist) {#s0075}

A human monoclonal antibody particularly targets and neutralizes IL-1β thus blocking its binding with IL-1 receptors ([@b0160]). A randomized, controlled and double-blind study are underway in which 450 participants are to be enrolled, to check the efficiency and safety of canakinumab in patients with COVID-19 induced pneumonia and systemic inflammatory release syndrome (SIRS). Until date, this drug has been passed from phase 2 trials and the estimation date for the completion of clinical trials study is October 16, 2020. The dose of canakinumab administered by patients according to body weight (40--60 kg, 450 mg; 60--80 kg, 600 mg;\>80 kg; 750 mg) along with 5% dextrose (iv fluid) for 2 h ([@b0345]).

4.4. IL-6 receptor antagonist {#s0080}
-----------------------------

These classes of drugs blocks interleukin (IL-6) mediated signaling pathways by binding competitively with soluble and membrane bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 involved in various physiological process like activation of T-cells, B-cell, hematopoietic cell proliferation and differentiation, hepatic acute-phase protein synthesis initiation and also immunoglobulin secretion([@b0440]).

### 4.4.1. Tocilizumab {#s0085}

It is a monoclonal antibody, firstly initiates and tested by china to decrease the lung related complications in patients with COVID-19. A randomized and retrospective study showed that tocilizumab plays a beneficial role as an adjunctive therapy in COVID-19 patients. Preliminary data proved that percentage of lymphocyte, concentration of CRP, and computed-tomography clarity changes and reduces the hospitalization duration of these patients ([@b0525]). At present, three clinical trials are under advancement to assess its safety and efficacy alone or in combination with some other drugs by taking 1500 participants with SARS-CoV-2 infection ([@b0035], [@b0145], [@b0380]). The phase 3 clinical-trial of tocilizumab approved by US-FDA in severe COVID-19 pneumonia patients. Moreover, other IL-6 inhibitors such as *clazakizumab* and *sarilumab* are underway in the clinical trials (phase 2& 3) to evaluate its efficacy in COVID-19 infected patients ([@b0220]).

### 4.4.2. Itolizumab (ALZUMAb) {#s0090}

It is a humanized recombinant IgG1 anti-CD6 monoclonal antibody, used for the treatment of moderate to severe plaque psoriasis, rheumatoid arthriris and autoimmune disorders ([@b0390]). Initially, it was developed by [@b0050] in Bengaluru and approved in 2013 in psoriatic patients. Recently, Biocon repositioning the drug into patients with moderate to severe COVID-19 associated with Cytokine release syndrome (CRS) and acute respiratory distress syndrome (ARDS). In addition, Drug controller General of India (DCGI) allowed use of ALZUMAb (25 mg/5ml injection) in SARS-CoV-2 patients as an emergency treatment and capable to save numerous seriously sick patients with COVID-19 (<https://www.pharmaceutical-technology.com/news/biocon-itolizumab-approval/>).

Itolizumab is also acts as a immunomodulator and binds with CD6 receptor along with suppress many proinflammatory mediators (cytokines) and downregulates the T-cell activation at site of inflammation ([@b0390]). An open-label randomized and controlled study performed by Biocon, in 30 participants associated with moderate to severe symptoms of SARS-CoV-2 virus. The study being conducted in two groups, first group taken itolizumab + supportive care while second group only with supportive care. The overall outcomes showed there is no mortality rate and all patients are recovered well as compared to second group. Further, clinic-pathological observations i.e release of pro-inflammatory cytokines (IL-6 & TNF-α) significantly decrease in first group when compared to second group ([@b0265], [@b0470]). Moreover, several clinical studies are required to confirm its safety and efficacy in COVID-19 patients.

4.5. Aviptadil {#s0095}
--------------

It is a vasoactive intestinal polypeptide (VIP) analogue used in the treatment of erectile dysfunction, acute lung injury and Besnier-Boeck-Schaumann disease. The significance of aviptadil in ARDS, because it has been documented by animal studies that VIP is extensive concerted in the lungs and inhibits NMDA-induced caspase-3 activation, IL6 and TNF-α production and also protects against acidic (HCl)-induced lung edema. In the various animal models, aviptadil protects lungs and other organs from damage or failure by restoring barrier function at the alveolar interface ([@b0360], [@b0395]). In a phase 2 clinical trials, conducted under European regulatory authority (ERA), patients were successfully treated with intravenous infusion of aviptadil on escalating doses and restores all the functioning of pulmonary hypertension, acute lung injury and ARDS. Few adverse effects related to cardiovascular system such as change in blood pressure, heart rate or ECG was noticed.

4.6. Eculizumab {#s0100}
---------------

Eculizumab is a monoclonal protein based monoclonal antibody (mAb) used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica ([@b0510]). The main target of eculizumab is complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9, which is involved in many autoimmune diseases ([@b0205]). Based on case study of patients with SARS-CoV2 infection and also confirmed severe pneumonia and ARDS treated with i.v. infusion of eculizumab along with anticoagulant therapy (Enoxaparin 4000 IU/day s.c), antiviral therapy (LPV 800 mg/day + RTV 200 mg/day), hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamin C 6 g/day for 4 days. All patients showing decrease in the inflammatory markers including C-reactive protein (CRP) ([@b0165]). More clinical study is needed for confirmation its safety and efficacy as ananti-inflammatory in the treatment of COVID-19.

4.7. Janus kinase (JAK) inhibitors {#s0105}
----------------------------------

JAK are the intracellular enzymes located on cellular membrane, transmits signal by binding with various cytokines and growth receptors. After binding with receptor, enzymes phosphorylation occurs, which modulating the changes in the gene expression and thus, activates the signal transducers and activators of transcription proteins (STATs) ([@b0405]). JAK pathway is key enzyme and plays a crucial role in the activation of immune system, hematopoiesis and inflammation. Inhibitors of JAK, prevents the enzymes phosphorylation and activation of STATs proteins ([@b0355]).

### 4.7.1. Baricitinib {#s0110}

It is reversible and competitive inhibitor of JAK1 & JAK2, and firstlyaccepted by US FDA in the treatment of autoimmune disorder i.e. rheumatoid arthritis. It also have broad immunosuppressive effect, and used in many autoimmune disorders ([@b0500]). It blocks the enzymes protein kinase 1 related with AP2 (AAK1), thus inhibits the entry and binding of virus into the epithelial cell of the alveoli ([@b0320]). A non-randomized open label trial of baricitinib + LPV/RTV in 12 COVID-19 patients and a control group treated with HCQ + LPV/RTV. The respiratory function parameters in baricitinib-treated patients improve as compared to control group. No significant adverse effect reported in baricitinib-treated patients ([@b0075]). Further studies are needed to confirm its clinical safety and efficacy in the treatment of COVID-19 infection. Others JAK inhibitors are also under clinical development and data are being evaluated in the treatment of COVID-19 are *ruxolitinib* and *tofacitinib* ([@b0420]).

5. Adjuvant/supportive care {#s0115}
===========================

5.1. Isotretinoin {#s0120}
-----------------

Isotretinoin,a retinoid derivative of vitamin A, is used in the treatment of severe acne. It is the strongest down-regulator of ACE-2 receptors. It has been documented that isotretinoin is a protease inhibitors and can be a taken as a target therapy in COVID-19 ([@b0515]). Based on the above mechanism, isotretinoin currently tested under phase 3 clinical trials in the adult patients with positive SARS-CoV-2 viral infections. Current outcomes showing there is large difference at the onset of clinical signs and symptoms treated patients with isotretinoin, standard therapy or combined therapy and checked by on a daily basis.

5.2. Corticosteroids {#s0125}
--------------------

Corticosteroid therapy is only used as supportive care in patients of COVID-19 with refractory shock or ARDS ([@b0520]). According to WHO, corticosteroids are recommended only for some conditions like asthma, chronic obstructive pulmonary disease (COPD), and septic shock ([@b0495]). Earlier studies showed corticosteroids i.e. methyl-prednisolone directly not supported the patients having symptoms of viral-pneumonia in COVID-19 ([@b0260]), only act as an anti-inflammatory and reduces inflammatory mediators i.e. interleukin (IL-7 &IL-8), MCP1, Th1 chemokine,IP10 etc. ([@b0435], [@b0505]).

**Dexamethasone**, another cheap and widely steroid drug used in the treatment of many inflammatory disease conditions and disorders like asthma, severe skin allergies, chronic obstructive lung disease and certain cancers. Recently, it has been documented that dexamethasone could be life-saving drug in critically ill patients with COVID-19 ([@b0485]). A retrospective cohort study showed daily administered of dexamethasone (6 mg upto 10 days) reduces the mortality rate among patients with COVID-19 who needed supplemental oxygen and mechanical ventilation. There is no advantage of dexamethasone observed in patients who did not necessitate mechanical support or/ventilation ([@b0235]).

5.3. [@b0135] plasma {#s0130}
--------------------

It is an antibody-rich plasma, collected from the patients who already have recovered from diseases caused by virus e.g. polio, measles, ebola, H1N1 influenza, hepatitis B, and now currently in SARS-CoV-2 responsible for COVID-19. On May 1, 2020, US FDA permitted issued guidelines to healthcare providers, make ensure the safety and efficacy of investigational product by collecting plasma from recovered patients under demand of public health emergency ([@b0430]). A newly reports showed that use of plasma therapy in five ventilated coronavirus patients, all patients improved after one week of transfusion. Moreover, this report was not a clinical trial, further research is essential to confirm its potential and managing patients in SARS-CoV-2 infected patients (<https://clinicaltrials.gov/ct2/show/study/NCT04356534>).

5.4. Bronchodilators {#s0135}
--------------------

Bronchodilators are preferred only as a supportive care for COVID-19 patients associated with COPD, asthma and other respiratory disorders ([@b0300]). Due to concern of safety precautions, both standard nebulizers and metered dose inhalers (MDI) are risky to COVID-19 patients, as it requires opening of ventilator circuit. Regular administration of bronchodilator may be needed, to minimize the virus transmission to others multiple health care patient. In order to alleviate these hazards, Aeroneb Solo (Aerogen©, Galway, Ireland) has been successfully made for COVID-19 patients which continuously delivers medication via inhalation without circuit opening and requires minimal health-care workers for handling ([@b0325]).

5.5. Fibrinolytics {#s0140}
------------------

These are the agents that breakdown plasminogen to plasmin on the surface of thrombi, thus produced fibrinolysis ([@b0105]). A study was done in seriously unwell patients, already suffered with ARDS and respiratory collapse/failure. Patients administered with alteplase along heparin improves PaO2/FiO2 (P/F) ratio momentary approximately by 11--100% ([@b0335]). Further, detailed studies are required to check its clinical efficacy among large population. Others supportive fibrinolytic agents are also being evaluated for COVID-19 patients e.g. defibrotide ([@b0180]).

5.6. Anticoagulants {#s0145}
-------------------

Coronavirus patients have a higher risk of venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism ([@b0365]). Coagulopathy is one of the main reasons of mortality in the majority of COVID-19patients. A recent report suggested anticoagulant therapy such as low molecular weight heparin (LMWH) administered to 449 patients showed low mortality risk ([@b0270]). Aspirin is also used as a prophylaxis treatment in case of post-discharge VTE COVID-19 patients ([@b0020]). Further, additional data needed regarding its efficacy and safety in COVID-19 patients.

6. Conclusions {#s0150}
==============

Due to pandemic of COVID-19 disease, no vaccine or drug is approved to eliminate the virus. Drug development and discovery is broad and extensive process, due to utmost necessity of the treatment, drug repurposing is suitable for treatment of COVID-19 infection. At present, numerous drugs are ongoing clinical trial and tested directly in patients with COVID-19, strict monitoring is mandatory at the time of treatment of patients to assure its safety and efficacy of unknown profile of drugs. Based on the exposed and revealed structure and transmission mechanisms of novel coronavirus, the available treatment option is antiviral, anti-inflammatory & immunomodulatory drugs. This review provides detailed description of all available *in-vitro* & *in-vivo* studies, mechanism, clinical spectrum of disease, symptoms and safety concern profile of currently available treatment and concerning drugs, which are progress under clinical development. In conclusion, while waiting for the most effectual pharmacological treatment with less adverse effects, many trials are currently ongoing and will available around at the end of 2020, according to clinical trials government website. Hope, their consequences will definitely provide us good outcome and help worldwide in significant the greatest approach to cure or treat COVID-19 along with symptoms and complications.
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